Randomized comparison of cilostazol versus ticlopidine hydrochloride for antiplatelet therapy after coronary stent implantation for prevention of late restenosis.

No abstract is available for this paper.

• Publication year

  2002

• Venue

  American Heart Journal

• Publication date

  2002-08-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1067/MHJ.2002.122874PMID 12177649
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Effect of cilostazol on restenosis after coronary angioplasty and stenting in comparison to conventional coronary artery stenting with ticlopidine.

  2001cited by this paper
• Antiplatelet Is Superior to Anticoagulant Treatment After Coronary Stenting: Fewer Coronary and Other Events Within 30 Days After Stenting

  2000cited by this paper
• Clopidogrel instead of ticlopidine after coronary stent placement: is the switch justified?

  2000cited by this paper
• A randomized comparison of clopidogrel and aspirin versus ticlopidine and aspirin after the placement of coronary-artery stents.

  2000cited by this paper
• Reduction in the need for hospitalization for recurrent ischemic events and bleeding with clopidogrel instead of aspirin. CAPRIE investigators.

  2000cited by this paper
• Increased platelet aggregability in response to shear stress in acute myocardial infarction and its inhibition by combined therapy with aspirin and cilostazol after coronary intervention.

  2000cited by this paper
• Clopidogrel for prevention of major cardiac events after coronary stent implantation: 30-day and 6-month results in patients with smaller stents.

  2000cited by this paper
• Long term outcome after coronary stent implantation: a 10 year single centre experience of 1000 patients

  1999cited by this paper
• Impact of cilostazol on clinical and angiographic outcome after primary stenting for acute myocardial infarction.

  1999cited by this paper
• A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators.

  1999cited by this paper
• Usefulness of cilostazol versus ticlopidine in coronary artery stenting.

  1999cited by this paper
• Cilostazol inhibits the expression of activation-dependent membrane surface glycoprotein on the surface of platelets stimulated in vitro.

  1999cited by this paper
• Comparison of cilostazol versus ticlopidine therapy after stent implantation.

  1999cited by this paper
• Randomized evaluation of anticoagulation versus antiplatelet therapy after coronary stent implantation in high-risk patients: the multicenter aspirin and ticlopidine trial after intracoronary stenting (MATTIS).

  1998cited by this paper
• Lower expression of neutrophil adhesion molecule indicates less vessel wall injury and might explain lower restenosis rate after cutting balloon angioplasty.

  1998cited by this paper
• Cilostazol has beneficial effects in treatment of intermittent claudication: results from a multicenter, randomized, prospective, double-blind trial.

  1998cited by this paper
• Randomized multicenter comparison of conventional anticoagulation versus antiplatelet therapy in unplanned and elective coronary stenting. The full anticoagulation versus aspirin and ticlopidine (fantastic) study.

  1998cited by this paper
• Effects of cilostazol on late lumen loss after Palmaz-Schatz stent implantation.

  1998cited by this paper
• Antiplatelet treatment with cilostazol after stent implantation

  1998cited by this paper
• Clinical Significance of Neutrophil Adhesion Molecules Expression after Coronary Angioplasty on the Development of Restenosis

  1998cited by this paper
• The development of interventional cardiology.

  1998cited by this paper
• Use of cilostazol, a novel antiplatelet agent, in a post-Palmaz-Schatz stenting regimen.

  1997cited by this paper
• Effect of cilostazol in preventing restenosis after percutaneous transluminal coronary angioplasty.

  1997cited by this paper
• A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents.

  1996cited by this paper
• Comparison of aspirin alone versus aspirin plus ticlopidine after coronary artery stenting.

  1996cited by this paper
• P705 EXPRESSION OB ACTIVATION-DEPENDENT PLATELET MEMBRANE PROTEIN AFTER CORONARY ANGIOPLASTY : A ROLE IN ACUTE OCCLUSION OR LONG-TERM RESTENOSIS

  1996cited by this paper
• Expression of polymorphonuclear leukocyte adhesion molecules and its clinical significance in patients treated with percutaneous transluminal coronary angioplasty.

  1996cited by this paper
• Early detection of platelet activation after coronary angioplasty

  1996cited by this paper
• Meeting Highlights American College of Cardiology 45th Annual Scientific Session, Orlando, Florida, March 24 to 27, 1996

  1996cited by this paper
• Neutrophil and platelet activation at balloon-injured coronary artery plaque in patients undergoing angioplasty.

  1996cited by this paper
• Platelet activation and coronary stent implantation. Effect of antithrombotic therapy.

  1996cited by this paper
• Leukocyte activation with platelet adhesion after coronary angioplasty: a mechanism for recurrent disease?

  1995cited by this paper
• Anticoagulation after intracoronary stent insertion.

  1994cited by this paper
• A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group.

  1994cited by this paper
• A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators.

  1994cited by this paper
• Mechanisms of restenosis and redilation within coronary stents--quantitative angiographic assessment.

  1993cited by this paper
• Effect of Cilostazol, a Cyclic AMP Phosphodiesterase Inhibitor, on the Proliferation of Rat Aortic Smooth Muscle Cells in Culture

  1992cited by this paper
• A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. Ticlopidine Aspirin Stroke Study Group.

  1989cited by this paper
• Comparison of the inhibitory effects of cilostazol, acetylsalicylic acid and ticlopidine on platelet functions ex vivo. Randomized, double-blind cross-over study.

  1987cited by this paper
• The absorption, distribution and excretion of a new antithrombotic and vasodilating agent, cilostazol, in rat, rabbit, dog and man.

  1985cited by this paper
• Studies on 2-oxoquinoline derivatives as blood platelet aggregation inhibitors. II. 6-[3-(1-cyclohexyl-5-tetrazolyl)propoxy]-1,2-dihydro-2-oxoquinoline and related compounds.

  1983cited by this paper

• The quest for effective pharmacological suppression of neointimal hyperplasia.

  2020cites this paper
• Cilostazol attenuates intimal hyperplasia in a mouse model of chronic kidney disease

  2017cites this paper
• ilostazol Inhibits Leukocyte Integrin ac-1 , Leading to a Potential Reduction n Restenosis After Coronary Stent Implantation

  2016cites this paper
• Treatment with cilostazol improves clinical outcome after endovascular therapy in hemodialysis patients with peripheral artery disease.

  2016cites this paper
• Unexpected Discontinuation of Dual Antiplatelet Therapy within 14 Days after Percutaneous Coronary Intervention: A Single-center Case Series.

  2015cites this paper
• Comparison of cilostazol versus ticlopidine following coronary stenting in patients with coronary heart disease: A meta-analysis of randomized controlled trials

  2013cites this paper
• Chapter 34 – Peripheral Vascular Disease

  2013cites this paper
• Control of cilostazol release kinetics and direction from a stent using a reservoir-based design.

  2012cites this paper
• Therapeutic Potential of Oral Antiproliferative Agents in the Prevention of Coronary Restenosis

  2012cites this paper
• A Meta-Analysis of Randomized Controlled Trials Appraising the Efficacy and Safety of Cilostazol after Coronary Artery Stent Implantation

  2012cites this paper
• The Effectiveness and Safety of Triple‐Antiplatelet Treatment Based on Cilostazol for Patients Receiving Percutaneous Coronary Intervention: A Meta‐Analysis

  2012cites this paper
• Drug Class Review: Newer Antiplatelet Agents: Final Update 2 Report

  2011cites this paper
• Benefit, rather than safety, of cilostazol for long-term mortality in patients undergoing percutaneous coronary intervention: a meta-analysis of randomized trials.

  2011cites this paper
• Addition of Cilostazol to Aspirin and a Thienopyridine for Prevention of Restenosis After Coronary Artery Stenting: A Meta‐Analysis

  2010cites this paper
• Cilostazol reduces restenosis after carotid artery stenting.

  2010cites this paper
• Cilostazol Effectively Reduces the Decrease of Flow Volume in a Thrombotic Anastomosis Model in a Rat: A Novel Application of Ultrasonography for Evaluation

  2010cites this paper
• Effects of oral cilostazol 100 mg BID on long-term patency after percutaneous transluminal angioplasty in patients with femoropopliteal disease undergoing hemodialysis: a retrospective chart review in Japanese patients.

  2010cites this paper
• Efficacy of cilostazol in reducing restenosis in patients undergoing contemporary stent based PCI: a meta-analysis of randomised controlled trials.

  2009cites this paper
• Cilostazol in addition to aspirin and clopidogrel improves long-term outcomes after percutaneous coronary intervention in patients with acute coronary syndromes: a randomized, controlled study.

  2009cites this paper
• Systematic review and meta-analysis of randomized clinical trials appraising the impact of cilostazol after percutaneous coronary intervention.

  2008cites this paper
• Effects of long-term triple anti-platelet therapy with low-dose cilostazol after drug-eluting stent implantation

  2008cites this paper
• Cilostazol improves long-term patency after percutaneous transluminal angioplasty in hemodialysis patients with peripheral artery disease.

  2008cites this paper
• Effect of cilostazol on in-stent neointimal hyperplasia after coronary artery stenting: a quantative coronary angiography and volumetric intravascular ultrasound study.

  2007cites this paper
• Anti‐platelet and anti‐thrombotic approaches in patients undergoing percutaneous coronary intervention

  2007cites this paper
• Activation of Platelet Function Through G Protein–Coupled Receptors Platelets As Immune Cells: Bridging Inflammation and Cardiovascular Disease In Vivo Thrombus Formation in Murine Models Clinical Aspects of Platelet Inhibitors and Thrombus Formation Platelet Adhesion

  2007cites this paper
• Pharmacotherapy of Restenosis

  2007cites this paper
• Effects of Cilostazol on the Drug-Eluting Stent in Native Coronary Arteries

  2007cites this paper
• Improved Patency of Transjugular Intrahepatic Portosystemic Shunt: The Efficacy of Cilostazol for the Prevention of Pseudointimal Hyperplasia in Swine TIPS Models

  2007cites this paper
• Effects of angiotensin-converting enzyme inhibitors or an angiotensin receptor blocker in combination with aspirin and cilostazol on in-stent restenosis.

  2006cites this paper
• A prospective randomized antiplatelet trial of cilostazol versus clopidogrel in patients with bare metal stent.

  2006cites this paper
• Antiplatelet Therapy after Percutaneous Coronary Intervention

  2006cites this paper
• The Effects of Cilostazol on Proliferation of Vascular Smooth Muscle Cells and Expression of iNOS and p 21

  2006cites this paper
• Análise comparativa da hiperplasia intimal após o implante de stents com e sem sirolimus em artérias coronárias de pequeno calibre

  2006cites this paper
• Antiplatelet Therapy after Percutaneous Coronary Intervention

  2006cites this paper
• Aspirin and Antiplatelet Agents in the Prevention of Complications of Coronary Artery Disease

  2006cites this paper
• Comparative inhibitory effects of cilostazol and ticlopidine on subacute stent thrombosis and platelet function in acute myocardial infarction patients with percutaneous coronary intervention.

  2005cites this paper
• RACTS: A Prospective Randomized Antiplatelet Trial of Cilostazol Versus Ticlopidine in Patients Undergoing Coronary Stenting: Long-Term Clinical and Angiographic Outcome

  2005cites this paper
• Platelets and new antiplatelet drugs

  2005cites this paper
• Comparison of cilostazol and ticlopidine coadministered with aspirin for long-term efficacy and safety after coronary stenting; a meta-analysis

  2005cites this paper
• Comparison of Clopidogrel versus Cilostazol in CoronaryArtery Stenting

  2005cites this paper
• Randomized comparison of cilostazol vs ticlopidine for antiplatelet therapy after coronary stenting.

  2005cites this paper
• Cilostazol reduces target lesion revascularization after percutaneous transluminal angioplasty in the femoropopliteal artery.

  2005cites this paper
• Cilostazol improves long-term outcomes after coronary stent implantation.

  2005cites this paper
• Antithrombotic therapy during percutaneous coronary intervention: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.

  2004cites this paper
• Effects of Cilostazol on Platelet Activation in Coronary Stenting Patients Who Already Treated with Aspirin and Clopidogrel.

  2004cites this paper
• Cilostazol inhibits leukocyte integrin Mac-1, leading to a potential reduction in restenosis after coronary stent implantation.

  2004cites this paper
• Comparison of Cilostazol and Ticlopidine for One-Month Effectiveness and Safety after Elective Coronary Stenting

  2004cites this paper
• Cilostazol, clopidogrel or ticlopidine to prevent sub-acute stent thrombosis: a meta-analysis of randomized trials.

  2004cites this paper
• The Effects of Cilostazol on Proliferation of Vascular Smooth Muscle Cells and Expression of iNOS and p21

  2004cites this paper
• High Plasma Heparin Cofactor II Activity Is Associated With Reduced Incidence of In-Stent Restenosis After Percutaneous Coronary Intervention

  2004cites this paper
• Análise volumétrica da hiperplasia intimal intra-stent em pacientes diabéticos tratados com e sem abciximab

  2004cites this paper
• Effect of cilostazol, a phosphodiesterase inhibitor, on carotid IMT in Japanese type 2 diabetic patients.

  2004cites this paper
• THE ROLE OF CILOSTAZOL (PLETAL™) IN THE MANAGEMENT OF INTERMITTENT CLAUDICATION

  2003cites this paper
• The effect of hydrocortisone on reducing rates of restenosis and target lesion revascularization after coronary stenting less than 3 mm in stent diameter.

  2003cites this paper
• Thrombozytenaggregationshemmer

  2003cites this paper
• Central venous catheter occlusion and thrombosis.

  2003cites this paper
• Current world literature Arrhythmias

  2002cites this paper